Search company, investor...
Neovacs company logo


Founded Year




Date of IPO


Market Cap


About Neovacs

Neovacs is a Paris-based vaccine company working on anti-body therapies against human cytokines with an active immunization approach. Its platform is used to develop vaccine products that are inducing e.g. an anti-TNF, anti-VEGF, and anti-IFN polyclonal responses, and that are targeting broad pharmaceutical markets.

Headquarters Location

3-5 Impasse Reille

Paris, 75014,


+33 (0)1 53 10 93 00

Missing: Neovacs's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Neovacs's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Neovacs

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Neovacs is included in 1 Expert Collection, including Cancer.



1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Neovacs Patents

Neovacs has filed 1 patent.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immunology
  • Allergology
patents chart

Application Date

Grant Date


Related Topics




Autoimmune diseases, Immunology, Monoclonal antibodies, Immune system, Clusters of differentiation


Application Date


Grant Date



Related Topics

Autoimmune diseases, Immunology, Monoclonal antibodies, Immune system, Clusters of differentiation



Latest Neovacs News

Pharnext announces that Neovacs has set-up a management trust to manage the Pharnext securities issued and the rights and obligations of Neovacs under the financing agreement signed on September 30th,

Oct 31, 2022

31-Oct-2022 / 18:30 CET/CEST The issuer is solely responsible for the content of this announcement. Pharnext announces that Neovacs has set-up a management trust to manage the Pharnext securities issued and the rights and obligations of Neovacs under the financing agreement signed on September 30th, 2022   Neovacs is setting up a management trust (the “Trust”), with Equitis Gestion as trustee, of which it is both settlor and beneficiary, to manage its rights and obligations as well as the Pharnext securities issued respectively to Neovacs and the Trust, under the financing agreement signed on September 30th, 2022 between Neovacs and Pharnext. Under this agreement, the Trust is transferred all of Neovacs' rights and obligations under the OBSA Agreement, the outstanding warrants, simple bonds and share purchase warrants held by Neovacs, Neovacs' receivables from Pharnext to be equitized, as well as the security interests granted to Neovacs by Pharnext. PARIS, France, on October 31st, 2022 at 6:30pm (CET) – Pharnext SA (FR0011191287 - ALPHA) (the “Company”), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces the conclusion of an agreement with Neovacs for the establishment by Neovacs of a management trust (the “Trust”), with Equitis Gestion as trustee (the "Trustee"), to exercise all of the rights and satisfy all of the obligations of the latter as well as manage the Pharnext securities issued by Pharnext respectively to Neovacs and the Trust, respectively, under the OBSA Agreement signed on September 30th, 2022 between Pharnext and Neovacs (the "Trust Agreement"). As announced on October 3rd, 2022, Neovacs and Pharnext entered into an agreement on September 30th, 2022 for the issuance and subscription of warrants to purchase simple bonds, with warrants to purchase shares attached if applicable (the "OBSA Agreement"). [1]   Under the terms of the OBSA Agreement, Neovacs has undertaken to finance Pharnext up to a total nominal amount of €21,093,800, by subscribing to 224,647 warrants (the "BSO") giving access to a maximum of 224,647 simple bonds of one hundred euros (€100) nominal value each (the "Simple Bonds"), in several tranches (each, one "Tranche"), by the payment of (i) one Tranche at a net subscription price of €10,700,000, (ii) two Tranches at a net subscription price of €2,500,000  each, (iii) two Tranches at a net subscription price of €1,000,000 each, and (iv) six Tranches at a net subscription price of €500,000 each, pursuant to the OBSA Agreement. Under the OBSA Agreement, warrants to subscribe for shares were attached to the Simple Bonds issued in the first Tranche (the "BSAP"). On September 30th, 2022, Pharnext issued the first Tranche of the Simple Bonds, which was subscribed to by Neovacs at a net subscription price of €10,700,000. A total of 1,994,667,284 BSAP attached to the first Tranche of Simple Bonds were thus issued on September 30th, 2022. In addition, the OBSA Agreement allows the equitization of certain receivables (i.e. the conversion of a receivable into shares to which it is subscribed by way of debt set-off) held by Neovacs with respect to Pharnext, (namely; (i) the interest and fees on the €2.5 million loan granted by Neovacs to Pharnext in August 2022; (ii) the interest on the outstanding Bonds (equal to 1% per month); (iii) the commitment fee due by Pharnext to Neovacs under the OBSA Agreement; and (iv) under certain conditions, the principal amount of the Bonds in order to exercise, by way of debt set-off against their exercise price, share subscription warrants to be issued free of charge to the Trust by Pharnext, the number of which corresponds to the issue amount remaining from the authorized amount under the 11th resolution of the extraordinary general meeting dated March 21, 2022, as at September 30, 2022 (the "BSAE") and, if applicable, against the exercise price of the BSAP set at €0.01. In accordance with the OBSA Agreement, Neovacs and Pharnext have agreed on the terms and conditions of the Trust Agreement. This agreement defines the terms and conditions of the transfer by Neovacs to the Trustee on behalf of the Trust (i) of all of Neovacs' rights and obligations under the OBSA Agreement, (ii) of the outstanding BSO, Simple Bonds and BSAP, as well as all receivables to be equitized (iii) of the benefit of the security interests held by Neovacs in the context of the OBSA Agreement, such that as of said date the Trust will automatically be the beneficiary of such security interests and Neovacs will no longer be the beneficiary of any security interest in respect of Pharnext. Under the terms of the Trust Agreement, the Trustee will hold these assets within the trust estate during the term of the Trust, and will manage and administer them for the exclusive purpose of carrying out the mission defined in this agreement, per the terms and conditions described in Appendix, with the obligation for the Trustee to definitively transfer the ownership of the trust estate to Neovacs according to the periodicity and conditions provided for in the Trust Agreement, in accordance with the provisions of Articles 2011 and subsequent of the Civil Code. It is reminded that the OBSA Agreement provides that following the decision to exercise, if any, BSAE or BSAP by the Trust, the sales of Pharnext shares by the Trust may not represent more than 15% of the daily traded volumes. This rate may be increased to 30% in the event of the occurrence of certain events.

Neovacs Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Neovacs Rank

Neovacs Frequently Asked Questions (FAQ)

  • When was Neovacs founded?

    Neovacs was founded in 1993.

  • Where is Neovacs's headquarters?

    Neovacs's headquarters is located at 3-5 Impasse Reille, Paris.

  • What is Neovacs's latest funding round?

    Neovacs's latest funding round is IPO.

  • Who are the investors of Neovacs?

    Investors of Neovacs include Truffle Capital, Novartis Venture Funds and OTC Agregator.

  • Who are Neovacs's competitors?

    Competitors of Neovacs include Humanetics, Symphogen, Immune Design, Profectus BioSciences, Vaxart and 12 more.

Compare Neovacs to Competitors

FluGen Logo

FluGen is developing a universal influenza vaccine. The REDEE FLU influenza vaccine contains mutations in the M2 gene of the virus. The mutated virus can infect cells, express the entire spectrum of influenza RNA and proteins, yet fails to produce any infectious virus particles.

Lofarma S.p.A.

nnFor more than fifty years, the company have been plotting the route in Allergy medicine. The company have been leading generations of allergists to some of the most discoveries in this science:na vaccine by bronchial route, a vaccine by nasal route, the Methacholine Challenge Test, the Test Dose for foodstuff or additives allergy, and allergens adsorbed on single-use needles.


ImmBio is a vaccine company developing vaccine systems. The portfolio addresses areas of high unmet need, where the risk and consequence of infection are severe.


Vaxent has developed a StepNovA vaccine for Group A streptococcus


Creatogen, a spin-off from the Max Planck Institute for Infection Biology in Berlin, develops bacterial carriers for oral delivery to treat and prevent acute and chronic diseases caused by an imbalance of the immune system.

Prokaryon Technologies

Prokaryon Technologies, Inc., is a animal health company that develops solutions for the prevention and control of economically devastating diseases in food animals. The focus of the company is the discovery, development, and commercialization of veterinary products. Prokaryon's lead product is a genomics-derived vaccine to prevent shipping fever in cattle.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.